

# HEALTHCARE SECTOR BULLETIN

September 2015

QUADRIA  
CAPITAL

## HEALTHCARE TRENDS & IMPACT STORIES

---

Country: Vietnam

Headline: ***Vietnam attracts Cambodian medical tourists***

Summary: Local and Vietnamese sources suggest that there is an increase in the number of outbound Cambodian medical tourists and that there is a shift from the now high priced Singapore to the more affordable Vietnam, except where specialist treatment only available in Singapore is needed. Cambodian incomes are rising, so more people can choose to go overseas for health care.

The number of hospitals in Vietnam has increased; with better quality and a wider range of services. So more are able to offer treatment to medical tourists. These include the international hospitals - FV Hospital, Saigon Ito, Vu Anh International Hospital and Vinmec International Hospital.

Link <http://www.imtj.com/news/vietnam-attracts-cambodian-medical-tourists/>

---

Country: India

Headline: ***Foreign hospital operators buy their way into India***

Summary: For nearly two years, Parkway Pantai has delayed the opening of its 450-bed India hospital - the Singapore-based medical firm's bid to cash in on one of Asia's fastest-growing private healthcare markets - while it waited for the necessary permits. Estimates put the private hospital market at USD 55bn (SGD 78bn) a year, but firms must obtain as many as 70 clearances from the federal and local authorities to launch a new facility.

Expanding through acquisitions has increasingly become the tactic of choice for hospital operators seeking to grow quickly in India, where demand for private healthcare is booming thanks to an overburdened public healthcare system. Growing through acquisitions is more lucrative for hospital firms than starting from scratch. BofA-ML data shows they pay up to USD 150,000 to set up a new bed in India - against USD 60,000 to buy an existing bed. Also, acquisitions in India remain cheaper than in many other countries. Buying a hospital bed costs USD 1.5m in Singapore and USD 100,000 in South Africa, the data shows.

So far this year, IHH Healthcare has bought majority stakes in India's Global Hospitals and Continental Hospitals for about USD 240m. It already holds a 10.85% stake in India's largest hospital chain, Apollo Hospitals.

Link <http://www.straitstimes.com/business/foreign-hospital-operators-buy-their-way-into-india>

---

## HEALTHCARE SECTOR NOTABLE TRANSACTIONS

Country: Vietnam

Headline: ***T&T group is strategic investor in Transportation Hospital***

Summary: Vietnam-based multi-sector investment firm T&T Group has become a strategic shareholder in the Vietnam Central Transportation Hospital, the first medical facility to be equitised in Vietnam.

The hospital, owned by the Ministry of Transport, plans to launch an IPO this month. The hospital said they had received two applications from T&T Group and Bao Son Investment, Construction and Tourism Company. T&T met all the demands of capital and they also committed to support the operation of the hospital after equitisation and maintain the maximum of the existing workforce there, while Bao Son did not satisfy any of the criteria.

As planned, the state will hold 30% of the hospital's charter capital, while the hospital's staff will have 8.7%. Some 30% will be for strategic investors and the remainder 31.3% will be auctioned in the IPO.

The Vietnam Central Transportation hospital was estimated at a value of VND 158bn (USD 7.4m), which includes 86% state capital. After its equitisation, it is expected to have a charter capital of VND 168bn (USD 7.8m), equivalent to 16.8m shares.

The hospital, which is a 21,200 square metre facility located in Hanoi, recently opened a health-care building on a total investment of USD 15m.

Links: <http://www.dealstreetasia.com/stories/vn-dealbook-tt-group-to-become-strategic-investor-of-transportation-hospital-sun-group-spends-217-7-million-on-phu-quoc-entertainment-centre-an-phat-real-estate-to-take-controlling-stake-at-v-11588/>

Country: India

Headline: ***Carlyle Group buys 37% stake in Metropolis Healthcare***

Summary: Global private equity firm Carlyle Group has acquired 37% stake in diagnostic chain Metropolis Healthcare by buying out the share of its promoter GSK Velu and his affiliates for an undisclosed sum.

Commenting on the development, Carlyle Asia Buyout Team Managing Director Neeraj Bharadwaj said, "We are delighted to partner with Metropolis and back its promoter as well as its management team, and will leverage our healthcare industry expertise to support the company's growth plans."

The diagnostic chain has over 125 laboratories along with collection centres across seven countries - India, Sri Lanka, the UAE, South Africa, Kenya, Mauritius and Ghana.

Metropolis Healthcare plans to invest around INR 120 crore to add 40 laboratories and around 700 collection centres across India and abroad by the end of next financial year.

Links: <http://www.businesstoday.in/current/corporate/carlyle-group-buys-37percent-stake-in-metropolis-healthcare/story/223614.html>

## TRANSACTION NEWS

Date	Headlines	Summary
30-Sep	<b>Medicon 50% stake to be acquired by CR Bard for USD 25m (Source: Stock Exchange Announcement (Translated))</b>	Kobayashi Pharmaceutical [TYO: 4967], the Japan-based pharmaceutical company, announced today it has decided to sell its 50% stake in Osaka-based medical equipment joint venture Medicon to partner C.R. Bard. New Jersey-based medical devices company C.R. Bard [NYSE:BCR] currently holds a 50% stake in Medicon.
30-Sep	<b>Fuan Pharmaceutical (Group) in talks to buy Yantai Justaware Pharmaceutical for USD 236m (Source: Stock Exchange Announcement (Translated))</b>	Fuan Pharmaceutical (Group) [Fu An Yao Ye; SZ: 300194], a China-based listed pharmaceutical company, disclosed in a stock exchange announcement dated 30 September that it is in talks to buy Yantai Justaware Pharmaceutical [Zhi Chu Yao Ye]. Yantai Justaware Pharmaceutical is engaged in R&D, production and sales of Active Pharmaceutical Ingredient (API).
30-Sep	<b>Sun Pharmaceutical Industries commences tender offer for InSite Vision (Source: Company Press Release(s) (Edited))</b>	The India-based Sun Pharmaceutical Industries (BOM:524715, Sun Pharma) announced on 29 September 2015 that it has commenced a tender offer through its indirect wholly owned subsidiary, Thea Acquisition Corporation, for all of the outstanding shares of common stock (the "Shares") of the California-based InSite Vision (OTCBB:INSV) for USD.
30-Sep	<b>Hao Wen Holdings signs Lol to acquire a company engaged in manufacturing and selling of medicine in China (Source: Stock Exchange Announcement*)</b>	Hao Wen Holdings [HKG: 8019], a biodegradable products and raw materials trading company, announced that it has signed a non-legally binding letter of intent to acquire a company engaged in manufacturing and selling of medicine in China: This announcement is made by Hao Wen Holdings Limited (the "Company") pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on The Growth Enterprise Market of The Stock Exchange (the "GEM Listing Rules") and the Inside Information Provisions under Part XIVA of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong).
29-Sep	<b>Zhongyuan Union Cell and Gene Engineering ends proposed significant assets restructuring (Source: Stock Exchange Announcement(s) (Translated))</b>	Zhongyuan Union Cell and Gene Engineering [Zhong Yuan Xie He; SHA: 600645], a listed Chinese bioengineering technology company, has announced the termination of its proposed significant assets restructuring. According to the company stock exchange announcement tonight, it has been advised by the financial advisor China Minsheng Investment over halting its proposed tender offer for the Singapore-listed Cordlife Group [SGX: P8A).
29-Sep	<b>Shenzhen Hepalink Pharmaceutical terminates plan to buy stakes in two pharmaceutical firms (Source: Stock Exchange Announcement (Translated))</b>	Shenzhen Hepalink Pharmaceutical [Hai Pu Rui; SZA: 002399], a listed Chinese biological products company, said in a stock exchange announcement that it has terminated the proposal to buy stakes in a domestic pharmaceutical company and an overseas one. Shenzhen Hepalink Pharmaceutical has failed to reach agreements with the vendors over prices and business consolidations following the acquisitions after several rounds of negotiations.
29-Sep	<b>Zhongyuan Union advised by China Minsheng on halting Cordlife tender offer (Source:Stock</b>	Zhongyuan Union Cell and Gene Engineering [Zhong Yuan Xie He; SHA: 600645], a listed Chinese bioengineering technology company, has been advised by the financial advisor China Minsheng Investment over halting its proposed tender offer for the

29-Sep	<b>Exchange Announcement (Translated))</b> <b>China Meheco, Jiangxi Nanhua Medicine to form a CNY 100m JV (Source: Stock Exchange Announcement (Translated))</b>	<i>Singapore-listed Cordlife Group [SGX: P8A]. According to the stock exchange announcement by Zhongyuan Union Cell and Gene Engineering today: Cordlife Group. China Meheco [Zhong Guo Yi Yao; SH: 600056], a Beijing-based, listed Chinese pharmaceutical company, said in a stock exchange announcement today that its board meeting has approved to form a JV with Jiangxi Nanhua Medicine [Jiang Xi Nan Hua Yi Yao]. Jiangxi Nanhua General Medicine [Jiang Xi Nan Hua Tong Yong Yi Yao], the JV, will have a registered capital of CNY 100m (USD 15.7m) and will be engaged in pharmaceutical distribution business.</i>
29-Sep	<b>Shandong Weigao Orthopaedic Device files for Hong Kong IPO; UBS and CICC are joint sponsors (Source: Stock Exchange Announcement*)</b>	<i>Shandong Weigao Orthopaedic Device Company Limited, a China-based medical devices company, has filed an application to list on the Main Board of the Hong Kong stock exchange. UBS and CICC are the joint sponsors of the share offer. The company reported revenues of CNY 592m (USD 93m) in FY14.</i>
29-Sep	<b>Apiam considering AUD 100m IPO – report (Source: Australian Financial Review)</b>	<i>Apiam, the Australian veterinary business, is considering an AUD 100m (USD 71.09m) IPO, the Australian Financial Review reported. According to the report in the paper’s Street Talk column, which did not cite sources, this week Shaw and Partners will launch a pre-IPO roadshow.</i>
29-Sep	<b>GP2U stake acquired by Sonic Healthcare (Source: Australian Financial Review)</b>	<i>Sonic Healthcare [ASX: SHL] has secured a 12.5% stake in GP2U, the Australian telehealth startup, the Australian Financial Review reported. The paper cited Sonic clinical services’ group executive, Scott Beattie, as saying that Sonic was impressed with GP2U’s platform and decided to invest in the business.</i>
28-Sep	<b>Winsan (Shanghai) Medical Science and Technology in share trading halt over planned acquisition of a medical company (Source: Stock Exchange Announcement (Translated))</b>	<i>Winsan (Shanghai) Medical Science and Technology [Yun Sheng Shi Ye; SHA: 600767], a China-based listed medical equipment maker, has been in share trading halt since 8 September due to planned significant assets restructuring. According to the stock exchange announcement by the listed medical equipment manufacturer, it is expecting to complete the acquisition via both cash payment and new share issuance and the vendor will be a third-party company.</i>
28-Sep	<b>Sogo Rinsho Holdings to be merged with EPS Holdings on 1 January 2016 (Source: Stock Exchange Announcement (Translated))</b>	<i>EPS Holdings [TYO: 4282], the Japan-based medical-related services provider, and Sogo Rinsho Holdings [TYO: 2399], the Japan-based clinical trial support company, jointly announced today an agreement contract to merge operations effective 1 January 2016. Under the agreement reached today by the boards of both companies, EPS Holdings will become the wholly owning parent and Sogo Rinsho Holdings will become the wholly owned subsidiary.</i>
28-Sep	<b>Beijing Centergate Technologies (Holding) subsidiary signs Lol to buy Duoduo Pharmaceutical (Source: Stock Exchange Announcement (Translated))</b>	<i>A subsidiary of Beijing Centergate Technologies (Holding) [Zhong Guan Cun; SZ: 000931], a listed company engaged in real estate and pharmaceuticals, has signed a letter of intent to acquire a controlling stake in Duoduo Pharmaceutical [Duo Duo Yao Ye].</i>
26-Sep	<b>Guangxi Wuzhou Zhongheng may face changes in controlling shareholder (Source: Stock</b>	<i>Guangxi Wuzhou Zhongheng [Zhong Heng Ji Tuan; SHA: 600252], a listed Chinese pharmaceutical company, may be faced with changes in the controlling interest of the listed company. According to stock exchange announcement by the listed company</i>

	<b>Exchange Announcement (Translated))</b>	today (26 September), Zhongheng Industry [Zhong Heng Ji Tuan] currently holds a 22.52% stake in the company.
25- Sep	<b>China Shineway Pharmaceutical to acquire Beijing Wanter Bio-pharmaceutical for CNY 400m (Source: Stock Exchange Announcement*)</b>	China Shineway Pharmaceutical [HKG:2877] announced that it has signed an agreement to acquire Beijing Wanter Bio-pharmaceutical Co., Ltd. for CNY 400m (USD 62.75m). Beijing Wanter Bio-pharmaceutical Co., Ltd. is a company established in the PRC in 2002 with limited liability. The registered capital of Beijing Wanter Bio-pharmaceutical Co., Ltd. is CNY 8m.
25- Sep	<b>Guangzhou Improve Medical Instruments to buy certain state-owned assets (Source: Stock Exchange Announcement (Translated))</b>	Guangzhou Improve Medical Instruments [Yang Pu Yi Liao; CHI: 300030], a Chinese medical equipment maker whose shares have been suspended from trading since 30 July, is planning to buy state-owned assets via a new share issue. According to the stock exchange announcement by the company, it will have to undergo procedures required for the sale of state-owned assets and, due to the relatively complex procedures, the share-trading suspension will remain.
25- Sep	<b>Beijing Chunlizhengda Medical Instruments' board approves proposed application for listing of its shares in China (Source: Stock Exchange Announcement*)</b>	Beijing Chunlizhengda Medical Instruments (HKG: 1858), a Beijing-based orthopedic medical device company, announced that its board has approved the proposed application for the listing of its shares in China: This announcement is made by Beijing Chunlizhengda Medical Instruments Co., Ltd.
25- Sep	<b>Guangzhou Baiyunshan, Siemens to form medical diagnosis JV (Source: Stock Exchange Announcement (Translated))</b>	Guangzhou Baiyunshan Pharmaceutical (Baiyunshan) [SHA:600332; HKG:0874], a listed Chinese pharmaceutical company, said in a stock exchange announcement that it has signed a LoI with a Siemens Shanghai unit to form a medical diagnosis joint venture in Guangzhou, China.
24- Sep	<b>Bringspring Science and Technology signs another framework agreement to buy 51% stake in MeeHealth for USD 20m (Source: Stock Exchange Announcement (Translated))</b>	Bringspring Science and Technology [Rong Ke Ke Ji; SZ: 300290] has inked another framework agreement to buy a 51% stake in MeeHealth [Mi Jian Xin Xi] for CNY 127.5m (USD 20m), according to a stock exchange announcement made today, 24 September. The bidder is a listed financial data solutions provider in China.
24- Sep	<b>Shanghai Kinetic Medical to buy remainder of two medical devices companies (Source: Stock Exchange Announcement (Translated))</b>	Shanghai Kinetic Medical [Kai Li Tai; SZ: 300326] said in a stock exchange announcement dated 24 September that it plans to buy the stakes that it does not already own in Essen Technology (Beijing) [Yi Sheng Ke Ji] and Jiangsu IDEAL Medical Science & Technology [Ai Di Er]. Shanghai Kinetic Medical is a listed medical equipment maker.
24- Sep	<b>Metropolis Healthcare will look at making acquisitions (Source: VCCircle)</b>	Metropolis Healthcare, the India-based pathology chain operator, said it would look at making acquisitions as part of its growth drive in the next three years, VCCircle reported. Ameera Shah, Metropolis' CEO, was cited for this information.
24- Sep	<b>Srivichai Vejvivat eyed by investor - report (translated)(Source: Thunhoon)</b>	Srivichai Vejvivat [BKK: VIH], a Thailand-based medical services provider, is a takeover target of a large investor, Thunhoon reported. Citing an unnamed source, the Thai-language report said the potential bidder plans to take over several hospitals and VIH is one of the targets.

26-Aug	<b><i>Jiangxi 3L Medicinal Products planning to relaunch IPO preparations - report (translated)(Source: Shanghai Securities News)</i></b>	<i>JiangXi 3L Medicinal Products (Jiang Xi 3L Yi Yong Zhi Pin), a Jiangxi-based, privately held medical equipment maker, is planning to relaunch its IPO preparations four months after its first IPO application was rejected by the China Securities Regulatory Commission (CSRC) in May this year, the Shanghai Securities News reported.</i>
24-Sep	<b><i>Health Care's major Australian rivals may be losing interest - report (Source: The Australian)</i></b>	<i>Major Australian hospital operators Ramsay [ASX: RHC] and Healthscope [ASX: HSO] may be losing interest in Health Care, the Australian hospital operator, The Australian's Dataroom reported. According to the report, which did not cite sources, Health Care's owner, Archer Capital, is believed to be opposed to buyers seeking to buy only a portion of the target.</i>
24-Sep	<b><i>Elder Pharmaceuticals board meeting on 28 September to consider proposal for sale of certain overseas subsidiaries of company (Source: Stock Exchange Announcement(s) (Editeds)</i></b>	<i>The India-based Elder Pharmaceuticals (BOM:532322) informed the BSE on 23 September 2015 that a meeting of the board of directors of the Company will be held on 28 September 2015, inter alia, to consider a proposal for sale of certain step-down overseas subsidiaries of the Company. Citing two undisclosed sources, the mint had said on 11 September 2015 that Elder Pharmaceuticals might decide to sell its factories located in both Maharashtra and Uttarakhand, in addition to some real estate assets, to help raise capital to repay its creditors.</i>
23-Sep	<b><i>Thane plant sold to Vidhi Research and Development by Pfizer for INR 1.78bn (Source: Stock Exchange Announcement(s) (Edited))</i></b>	<i>Pfizer Ltd (BOM: 500680), the India-listed subsidiary of New York-headquartered drug major Pfizer Inc (NYSE:PFE), has informed the BSE that it has entered into a Business Transfer Agreement (BTA) for the transfer of the Company's business at the Thane Plant.</i>
23-Sep	<b><i>Glenmark Pharma not focus on making acquisitions as part of its short-term business strategy - chairman (Source: Business Standard)</i></b>	<i>Glenmark Pharmaceuticals [BOM: 532296], the listed Indian pharma, said it would not focus on making any acquisitions as part of its short-term strategy, Business Standard reported. Glenn Saldanha, the company's chairman, was quoted as saying that valuations are currently high in the segment, adding that the company will focus instead on growing organically and developing a new product pipeline.</i>
23-Sep	<b><i>Serum Institute of India says talks on hold for selling 10% stake (Source: The Times of India)</i></b>	<i>Serum Institute of India, the India-based vaccines maker, said it has put its plans on hold for selling around 10% stakeholding in the company as a result of the global economic slowdown, The Times of India reported. Adar C Poonawalla, Serum Institute of India's CEO, was cited as saying that the company.</i>
23-Sep	<b><i>Icon Cancer Care expected to begin IPO preparations in 2016 following CEO appointment (Source: Australian Financial Review)</i></b>	<i>Icon Cancer Care, the Australian cancer care provider, is expected to begin IPO preparations in 2016, the Australian Financial Review reported. According to the report, Icon's owner Quadrant Private Equity is anticipated to engage a chief executive for the company within the next three months, an important first step ahead of the expected listing.</i>
23-Sep	<b><i>Guangdong Xinhui Meida Nylon cancels proposed acquisition of San MediTech (Huzhou) stake (Source: Stock Exchange Announcement (Translated))</i></b>	<i>Guangdong Xinhui Meida Nylon [Xin Hui Mei Da:SZ:000782], a Chinese chemical fiber company, has been in a share trading halt since 8 June due to its plans to buy a stake in San MediTech (Huzhou) [Sheng Mei Di Nuo Yi Liao], a blood sugar monitoring equipment maker.</i>

<b>23- Sep</b>	<b>Bangkok Dusit Medical in talks to take over hospitals in China, Myanmar (translated) (Source: Thunhoon)</b>	<i>Bangkok Dusit Medical Services [BKK: BDMS], a Thailand-based hospital group, is in talks to acquire hospitals in China and Myanmar, Thunhoon reported. Citing President Prasoet Prasatthongsot, the Thai-language report said that BDMS plans to expand its hospital business overseas as the company already has plans to operate 50 hospitals in Thailand in 2016 to 2017.</i>
<b>23- Sep</b>	<b>Narayana Hrudayalaya expected to file listing document with Sebi by this month's end for estimated INR 7bn IPO – report (Source: Mint)</b>	<i>India's Narayana Hrudayalaya, which operates the Narayana Health hospital chain, is likely to file its listing document by September-end with the country's capital markets regulator, the Securities and Exchange Board of India (Seb), VCCircle reported. Citing sources in-the-know, the paper said that Narayana Hrudayalaya is seeking to raise an estimated INR 7bn (USD 106.28m) via an initial public offering (IPO).</i>
<b>22- Sep</b>	<b>Furen Pharmaceutical Group Industry to halt share trading on 23 September, controlling shareholder planning significant assets restructuring (Source: Stock Exchange Announcement (Translated))</b>	<i>Furen Pharmaceutical Group Industry [Fu Ren Ji Tuan; SH: 600781], a Henan-based, listed pharmaceutical company, will enter into share trading halt on 23 September as its controlling shareholder Furen Pharmaceutical Group is planning a significant assets restructuring related to the listed company.</i>
<b>22- Sep</b>	<b>Link Healthcare to be acquired by Clinigen for up to GBP 100m (Source: Company Press Release(s) (Edited))</b>	<i>Clinigen Group plc ('Clinigen' or the 'Group', AIM:CLIN), the specialty global pharmaceutical company, has agreed to acquire Link Healthcare ('Link'), a specialist pharmaceutical and medical technology business focused on the Asia, Africa and Australasia ('AAA') region, for an initial consideration of GBP 44.5m and a maximum of approximately GBP 100m based on achievement of milestones (the 'Acquisition').</i>
<b>22- Sep</b>	<b>Bioton's supervisory board taken over by CEE Equity Partners and Harbin Gloria (translated)(Source: Puls Biznesu)</b>	<i>Private equity fund CEE Equity Partners, teamed up with the Chinese pharma company Harbin Gloria have taken over the supervisory board of the listed Polish insulin maker Bioton, Puls Biznesu wrote. After shareholders' meeting on 21 September, the seven-person board includes two representatives each of CEE Equity Partners and Harbin Gloria and two independent directors, one of whom is close to minority investor Zygmunt Solorz-Zak, the article said.</i>
<b>22- Sep</b>	<b>Hubei Aerospace Dule 57.61% stake put up for sale by China Aerospace Sanjiang for CNY 51.2m (USD 8.0m) (Source: Chinese Equity Exchange Announcement)</b>	<i>China Aerospace Sanjiang Group [Zhong Guo Hang Tian San Jiang], a Chinese state-owned company, has its 57.61% stake in Hubei Aerospace Dule Pharmaceutical up for sale from 22 September to 26 October. The asking price is CNY 51.2m (USD 8.027m), according to the announcement posted on the Shanghai United Assets and Equity Exchange.</i>
<b>21- Sep</b>	<b>Hainan Haiyao planning to raise up to CNY 4.5bn via private placement of new shares, part of the proceeds will go for assets purchase (Source: Stock Exchange Announcement (Translated))</b>	<i>Hainan Haiyao [Hai Nan Hai Yao; SZ: 000566], a China-based listed pharmaceutical company, said in a stock exchange announcement tonight that it plans to raise CNY 4.5bn (USD 707m) via a private placement of new shares. The company plans to sell new shares to a maximum of 10 investors and the proceeds will be used to fund the production projects related to its major business operation and acquisition of assets.</i>
<b>21- Sep</b>	<b>Shenzhen ET Medical Technology to be sold to Zhongzhu Holding for</b>	<i>Zhongzhu Holding [Zhong Zhu Kong Gu; SH: 600568], a China-based listed real estate developer, has signed an agreement to buy 100% of Shenzhen ET Medical Technology</i>

	<b>CNY 1.9bn (Source: Stock Exchange Announcement (Translated))</b>	<i>[Yi Ti Yi Liao] for CNY 1.9bn (USD 298.44m), according to a stock exchange announcement posted on 21 September.</i>
<b>21- Sep</b>	<b>Healthway Medical/International Healthway issue price of each consideration share changes to SGD 0.43 (Source: Stock Exchange Announcement(s))</b>	<i>Healthway Medical Corporation (SGX: 5NG), has announced amendment to the implementation agreement regarding proposed acquisition by International Healthway Corporation (SGX: 5WA), the Singapore-based healthcare services group. The issue price of each consideration share has been changed to SGD 0.43 from SGD 0.45.</i>
<b>21- Sep</b>	<b>Yihua Healthcare to buy Bioland Technology, Dazi Sailekang Medical, sells three subsidiaries (Source: Stock Exchange Announcement (Translated))</b>	<i>Yihua Healthcare [Yi Hua Jian Kang, SHE:000150], a China-based, listed medical services company, today (21 September) published on the stock exchange the details of acquisitions of two companies and the sale of three real estate developers.</i>
<b>20- Sep</b>	<b>Portea Medical receives USD 37.5m series B funding led by Accel (Source: Company Press Release(s) (Edited))</b>	<i>Portea Medical, the India-based home healthcare company, on 20 September 2015 announced that it has received a USD 37.5m in series B funding led by Accel (Accel Partners, the private-equity player). International Finance Corporation (IFC), a member of the World Bank Group; Qualcomm Ventures and Ventureast also participated in this round.</i>
<b>20- Sep</b>	<b>Kerala Institute of Medical Sciences valued at up to INR 18bn as PE backers plan exit - report (Source: Mint)</b>	<i>Ascent Capital and Orbimed, the private equity (PE) backers of Kerala Institute of Medical Sciences (KIMS), a private, India-based hospital company, are reportedly planning to exit from their stake in the company, mint reported citing two sources with knowledge of the sale. The two PE owners reportedly jointly own a significant-sized minority holding in KIMS.</i>
<b>20- Sep</b>	<b>Qinghai Gelatin to enter into share trading halt on 21 September, planning to buy 100% of Shenzhou Eqiao (Source: Stock Exchange Announcement (Translated))</b>	<i>Qinghai Gelatin [Qing Hai Ming Jia; SH:000606], a Shenzhen-listed pharmaceutical entity, will enter into share trading halt on 21 September due to planned significant assets restructuring According to a company stock exchange announcement dated 21 September, it is planning to buy 100% of Shenzhou Eqiao [Shen Zhou Yi Qiao], a Beijing-based, privately held financing and taxation services company, from private investor Peng Cong, and two companies Baida Yongxin (Beijing) Investment and Xinjiang Teda Xinyuan Equity Investment.</i>
<b>20- Sep</b>	<b>Strides Arcolab inks deal with Sun Pharmaceutical Industries to acquire CNS divisions of erstwhile Ranbaxy (Source: Company Press Release(s) (Edited))</b>	<i>The India-based Sun Pharmaceutical Industries (BOM:524715, Sun Pharma) and Strides Arcolab (BOM:532531, Strides) on 19 September 2015 announced that they have entered into a definitive agreement related to erstwhile Ranbaxy's 'Solus' and 'Solus Care' divisions operating in the central nervous system (CNS) segment in India.</i>
<b>19- Sep</b>	<b>Serum Institute of India negotiates 5%-10% stake sale with investors; CEO values company at up to USD 12bn – report (Source: Business Standard)</b>	<i>Serum Institute of India's owners are in negotiations with unnamed private equity (PE) firms and sovereign wealth funds concerning the possible sale of 5%-10% stake in the company, Business Standard reported. Adar Poonawalla, Serum Institute's CEO, was cited as saying that Serum wants a valuation of up to INR 800bn (USD 12bn) in the sale.</i>



<b>19- Sep</b>	<b>Rimsa draws strategic interest including Sanofi, Pfizer and Abbott – report (Source: Newswire Round-up)</b>	<i>Rimsa, a Mexico-based pharmaceutical company, has attracted takeover interest from firms including France-based Sanofi (PA: SEN), New York's Pfizer (NYSE:PFE), and Illinois' Abbott Laboratories (NYSE:ABT), according to a newswire report.</i>
<b>18- Sep</b>	<b>Rui Kang Pharmaceutical to acquire DVF Holdco (Cayman) Limited for HKD 103m (Source: Stock Exchange Announcement(s))</b>	<i>Rui Kang Pharmaceutical Group Investments (HKG: 8037), a consumer cosmetic, health related and pharmaceutical products manufacturer, announced that it has signed an agreement to acquire DVF Holdco (Cayman) Limited for HKD 103m (USD 13.3m).</i>
<b>18- Sep</b>	<b>Medicross to be acquired by Tempstaff (Source: Company Press Release*)</b>	<i>Tempstaff Co., a subsidiary of Japanese staffing service provider Temp Holdings Co., Ltd. [TYO: 2181], has decided to acquire all the outstanding shares of Medicross Corp., a contract research organisation based in Tokyo, Tempstaff said in a press statement.</i>
<b>18- Sep</b>	<b>Fortis Healthcare is evaluating proposals for possible sale of its Dubai pathology business (Source: Stock Exchange Announcement(s) (Edited))</b>	<i>India-based Fortis Healthcare [BOM: 532843] said it is currently evaluating proposals for the potential sale of its pathology business located in Dubai, according to a stock exchange announcement.</i>
<b>18- Sep</b>	<b>Serum Institute of India stake-sale talks now center on 5%-10% stake (Source: Newswire Round-up)</b>	<i>Serum Institute of India, an India-based vaccines producer, is now looking at a stake sale between 5 - 10% and is in discussions with private equity and sovereign wealth funds, according to a newswire report. This news service previously reported that the company was working with Citibank and EY on fundraising.</i>
<b>17- Sep</b>	<b>Dongliang New Material in talks to buy Wanbangde Pharmaceutical Group (Source: Stock Exchange Announcement (Translated))</b>	<i>Dongliang New Material (Dong Liang Xin Cai) [SZ: 002082], a China-based listed aluminum product maker, disclosed in a stock exchange announcement on 17 September that it is in talks to buy Wanbangde Pharmaceutical Group (Wan Bang De Zhi Yao). Wanbangde Pharmaceutical Group, formerly known as Zhejiang Wanbang Pharmaceutical, is a pharmaceutical company set up in 1970.</i>
<b>17- Sep</b>	<b>Shanghai Lansheng to auction Shanghai Lansheng Guo Jian Medicine and Shanghai CP Guojian Pharmaceutical stakes (Source: Stock Exchange Announcement (Translated))</b>	<i>Shanghai Lansheng (Lan Sheng Gu Fen) [SH: 600826] has decided to auction off a 34.65% stake in Shanghai Lansheng Guo Jian Medicine and a 0.73% stake in Shanghai CP Guojian Pharmaceutical [Zhong Xin Guo Jian] on the Shanghai United Assets and Equity Exchange.</i>
<b>17- Sep</b>	<b>Sinclair IS \$500m+ acquisition being considered by Lupin – report (Source: The Times of India)</b>	<i>Lupin [BOM: 500257], the Indian pharmaceutical company, is reportedly considering the acquisition of Sinclair IS Pharma [LON: SPH], the UK-based pharmaceutical company, according to a report by The Times of India that cited unidentified sources.</i>
<b>17- Sep</b>	<b>Baxter China intends to buy Shouhejinhai- report (translated) (Source: Shanghai Securities News)</b>	<i>Baxter China, a subsidiary of Baxter (NYSE: BAX), intends to buy Shouhejinhai [Shou He Jin Hai], a Qingdao-based pharmaceutical company, Shanghai Securities News reported, without identifying the information source. Due diligence has been close to completion and the acquisition plan is expected to be reached shortly, the source added in the Chinese-language daily.</i>
<b>17- Sep</b>	<b>Vitaco chasing acquisitions to</b>	<i>Vitaco [ASX: VIT] plans to pursue acquisitions to grow its global reach, The Australian</i>

**extend global reach (Source: The Australian)**

reported. The paper cited Vitaco Chief Executive Ryan d'Almeida as saying that the health and wellness space remains fragmented, offering scope for potential acquisitions.

17- Sep	<b>COL Capital offer letters for possible 39.48% stake in Lianyungang Jiatai Construction accepted (Source: Stock Exchange Announcement*)</b>	COL Capital (HKG:0383), the Hong Kong-listed financial services and property investment company, announced that its offer letters for the possible acquisitions of 39.48% stake in Lianyungang Jiatai Construction from various vendors for a total consideration of approximately CNY 592m (USD 93m) have been accepted: This announcement is made by COL Capital Limited (the "Company") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).
17- Sep	<b>Huangshi Daye Nonferrous Hospital Management 75% stake acquired by Humanwell Healthcare for CNY 106.4m (Source: Stock Exchange Announcement (Translated))</b>	Humanwell Healthcare [Ren Fu Yi Yao, SHE:600079], a listed, Chinese pharmaceutical company, said tonight in a stock exchange announcement that it has won the bidding for a 75% stake in Huangshi Daye Nonferrous Hospital Management [Huang Shi Da Ye You Se Yi Yuan] for CNY 106.4m (USD 16.72m). Huangshi Daye Nonferrous Hospital Management is a subsidiary of Daye Nonferrous Metals, a Hubei-based metal mining company.
17- Sep	<b>MEK-ICS files application for KOSDAQ IPO; Kiwoom Securities acting as manager (Source: Company Press Release (Translated))</b>	MEK-ICS, a South Korean medical equipment maker, has filed an application for regulatory approval for a proposed IPO, according to a Korea Exchange (KRX) statement disclosed today. The company plans to float on the KOSDAQ. Jong-cheol Kim, CEO at the company, owns a 28% of the company.
17- Sep	<b>Nanjing Xinjiekou plans framework agreement with Golden Meditech on China Cord Blood stakes (Source: Stock Exchange Announcement (Translated))</b>	Nanjing Xinjiekou Department Store [Nan Jing Bai Huo; SHE:600682], a China-based department store operator, said in a stock exchange announcement that it is planning to sign a framework agreement to acquire all the Chinese business of China Cord Blood Corporation [NYSE:CO].
17- Sep	<b>Pentax Medical invests in Creo Medical (Source: Fierce Medical Devices)</b>	Hoya [TYO: 7741], the Japan-based medical products company, announced today that its group company Pentax Medical has agreed to invest in UK-based electrosurgical devices company Creo Medical. 17 September 2015, Tokyo – HOYA Group company PENTAX Medical has entered into an agreement to invest in Creo Medical, a leading electrosurgical energy devices company based in the U.K.
17- Sep	<b>Sinopharm Industrial Investment puts 20% stake in Sinopharm Holding Medical Investment up for sale (Source: Chinese Equity Exchange Announcement)</b>	A 20% stake in Sinopharm Holding Medical Investment Management has been put up for sale with a bidding window of 20 working days, according to a 17 September announcement posted on the Shanghai United Assets and Equity Exchange. The asking price is CNY 100m (USD 15.706m) and the vendor is Sinopharm Industrial Investment [Guo Yao Chan Ye Tou Zi], the announcement said.
17- Sep	<b>Alliance HealthCare Services 51.5% stake to be acquired by</b>	Alliance HealthCare Services, Inc. (NASDAQ:AIQ) (the "Company," or "Alliance"), a leading national provider of outsourced healthcare services, announced today that

	<b>Fujian Thai Hot Investment for USD 102.5m (Source: Company Press Release(s))</b>	<i>Fujian Thai Hot Investment Co., Ltd (“Thai Hot”), has agreed to purchase approximately 5,537,945 shares of the Company’s common stock from funds managed by Oaktree Capital Management, L.P. (“Oaktree”), MTS Health Investors, LLC (“MTS”), and Larry C. Buckelew, for approximately USD 102.5m or USD 18.50 per share. Upon completion of the transaction, Thai Hot would own an aggregate of approximately 51.5% of the outstanding common stock of the Company.</i>
<b>17- Sep</b>	<b>Kyma Medical Technologies acquired by ZOLL Medical (Source: Company press release.)</b>	<i>ZOLL® Medical Corporation, an Asahi Kasei Group company that manufactures medical devices and related software solutions, today announced that it has acquired Tel Aviv, Israel-based Kyma Medical Technologies, Ltd., which develops technologies to measure early signs of congestive heart failure.</i>
<b>16- Sep</b>	<b>Rheintal - Klinik to be sold to Huapont-Nutrichem's German subsidiary for EUR 5.873m (Source: Stock Exchange Announcement (Translated))</b>	<i>Huapont-Nutrichem [Hua Bang Ying Tai, SHE:002004], a listed, Chinese, pharmaceutical company, has agreed to acquire, through its Germany-based subsidiary, 100% of Rheintal - Klinik from 13 investors for EUR 5.873m (USD 6.64m).</i>
<b>16- Sep</b>	<b>E for L Aim to divest stake in WCI Holding (Source: Stock Exchange Announcement(s) (Edited))</b>	<i>E for L Aim [BKK: EFORL], a Thailand-based medical equipment distributor, announced the disposal of a stake in its beauty clinic subsidiary WCI Holding (WCIH) for THB 495m (USD 13.74m). After E for L has disposed of the stake, WCI Holding will increase its capital from THB 1bn to THB 1.16bn by issuing 16m new shares to its existing shareholders to raise THB 800m for partial debt repayment.</i>
<b>16- Sep</b>	<b>ID Senim chain of ten kidney centres in Kazakhstan acquired by Diaverum (Source: Company Press Release(s))</b>	<i>Diaverum today announced the acquisition of the ID Senim chain of ten kidney centres in Kazakhstan. Diaverum now operates 19 clinics in the Republic of Kazakhstan having entered the country on 1 January this year with the acquisition of Nefros Asia. The acquisition was signed with ID Senim on 7 August 2015 with the transaction formally completed on 1 September.</i>
<b>16- Sep</b>	<b>Watami in final phase to agree with Sompo Japan for nursing care unit sale - report (translated) (Source: Nihon Keizai Shimbun)</b>	<i>Watami [TYO: 7522], a Japan-based restaurant and bar chain operator, is in the final stage in talks with Japanese insurer Sompo Japan Nipponkoa Holdings [TYO: 8630] to sell its its nursing care unit, Watami no Kaigo, the Nihon Keizai Shimbun reported.</i>
<b>16- Sep</b>	<b>Filter Vision plans to list medical unit in three to five years (translated)(Source: Thunhoon)</b>	<i>Filter Vision [BKK: FVC], a Thailand-based water treatment systems provider, plans to list its newly-established medical subsidiary, KT Medical Service (KTMS) in Thailand, Thunhoon reported. Citing Chairman Wichit Techakasem, the Thai-language report said that Filter Vision plans to list KTMS in the next three to five years.</i>
<b>16- Sep</b>	<b>COL Capital issues offer letters to acquire 39.48% stake in Lianyungang Jiatai Construction for total consideration of approximately CNY 592m(Source: Stock Exchange Announcement*)</b>	<i>COL Capital (HKG:0383), the Hong Kong-listed financial services and property investment company, announced that it has issued offer letters for the possible acquisitions of 39.48% stake in Lianyungang Jiatai Construction from various vendors for a total consideration of approximately CNY 592m (USD 93m).</i>
<b>16- Sep</b>	<b>InSite Vision terminates merger agreement with QLT (Source:</b>	<i>InSite Vision Inc. (OTCBB: INSV) today announced that InSite and a subsidiary of Sun Pharmaceutical Industries Ltd. (Sun Pharma) have entered into a merger agreement</i>

*This publication does not constitute an offer of, or the solicitation of, an offer to buy or subscribe for, any financial instrument or investment, nor shall it (or any part of it or the fact of its distribution) form the basis of, or be relied on in connection with or act as any inducement to enter into, any contract or commitment whatsoever.*

	<b>Company Press Release (s)</b>	
		<i>under which an indirect wholly owned subsidiary of Sun Pharma will acquire InSite in an all-cash transaction for USD 0.35 per share, or approximately USD 48m in aggregate equity value, on a fully diluted basis.</i>
<b>16- Sep</b>	<b>Strides Arcolab receives authenticated copy of court order approving scheme of amalgamation of Shasun Pharmaceuticals with company (Source: Stock Exchange Announcement(s) (Edited))</b>	<i>With reference to the earlier letter dated 28 August 2015, informing about the oral order approving the Scheme of Amalgamation (of the India-based Shasun Pharmaceuticals (BOM: 524552) with Strides Arcolab (BOM: 532531)) from the Hon'ble High Court of Bombay, Strides Arcolab informed the BSE on 15 September 2015 that the Company has now received an authenticated copy of the court order.</i>
<b>16- Sep</b>	<b>Tonghua Grape Wine share trading halt remains on 16 September, planning to buy pharmaceutical and healthcare assets (Source: Stock Exchange Announcement (Translated))</b>	<i>Tonghua Grape Wine [Tong Pu Gu Fen;SHA:600365], the China-based, listed winemaker, said in a stock exchange announcement today that its share trading halt, which took effect on 2 July, will remain on 16 September. The company is planning to buy assets via new share issuance or cash payment. The targets of acquisition will be companies in the pharmaceutical and healthcare sectors.</i>
<b>15- Sep</b>	<b>Hangzhou Tianmushan Pharmaceutical in share trading halt over planning significant assets restructuring (Source: Stock Exchange Announcement (Translated))</b>	<i>Hangzhou Tianmushan Pharmaceutical [Tian Mu Shan; 600671.SH], the Zhejiang-based listed pharmaceuticals company, has been in share trading halt since 31 August. According to the company stock exchange announcement tonight, it is planning a significant assets restructuring and therefore, its share trading halt will remain and is expected to last for one more month.</i>
<b>15- Sep</b>	<b>InSite Vision takeover offer submitted by Sun Pharma at estimated USD 45.16m equity valuation - report (Source: The Economic Times)</b>	<i>India's Sun Pharmaceutical Industries [BOM: 524715] has submitted an acquisition offer for InSite Vision Inc (OTCBB: INSV), the US-based specialty ophthalmologic products company, The Economic Times reported. Citing sources with knowledge of the matter, the report said that Sun Pharma submitted a takeover offer at an equity valuation of nearly INR 3bn (USD 45.16m).</i>
<b>15- Sep</b>	<b>Wuhan Easy Diagnosis Biomedicine plans M&amp;As for business expansion (translated)(Source: China Securities Journal)</b>	<i>Wuhan Easy Diagnosis Biomedicine [Ming De Sheng Wu; NEQQ: 430591], a Hubei-based, NEEQ-listed Chinese diagnostic products company, has M&amp;A plans for business expansion, China Securities Journal reported today. The company will focus on the Point-of-care testing (POCT) business and will be on the watch for M&amp;A opportunities in the upper and lower stream businesses, the Chinese-language paper, citing Chairman Chen Lili, added.</i>
<b>15- Sep</b>	<b>Modern Dental Group plans USD 250m Hong Kong IPO this year – report (translated) (Source: Apple Daily)</b>	<i>Modern Dental Group, a global dental prosthetic device provider, plans to raise USD 250m through getting listed in Hong Kong, according to an unsourced report in the Chinese language Apple Daily. The report added that the company hopes to get listed before the end of this year, but it has not yet commenced a road show for the IPO.</i>
<b>14- Sep</b>	<b>Swissray Global Healthcare 19.87% stake to be bought by Delta Electronics for USD 28.5m</b>	<i>Delta Electronics [TT:2308], the listed Taiwan-based industrial electronics parts maker, announced today (14 September) that its board has decided to acquire 28.18m shares, representing a 19.87% stake, in Swissray Global Healthcare Holding, according to a</i>

	<b>(Source: Stock Exchange Announcement (Translated))</b>	stock exchange announcement.
14- Sep	<b>Global Dental Services looks to raise up to USD 25m – report (Source: The Economic Times)</b>	Global Dental Services, the owner of Indian dental chain Clove Dental, is looking to raise up to USD 25m (INR 1.66bn) in Series C funding, and has already initiated talks with multiple unnamed venture capital (VC) firms for the purpose, The Economic Times reported.
14- Sep	<b>Aprogen to sell minority stake in Schnell Biopharmaceuticals in block deal (translated)(Source: Money Today)</b>	Aprogen, an unlisted, South Korean biosimilar developer, plans to sell a minority stake in Schnell Biopharmaceuticals (KRX: 003060) in a block deal, Money Today reported citing the vendor's CEO. Jae-seop Kim, the CEO at Aprogen, told the Korean-language newspaper that it will sell 3m-4m shares in the listed South Korean pharmaceutical company in a block deal.
14- Sep	<b>MCTTBIO applies for KOSDAQ IPO (translated) (Source: Stock Exchange Announcement (Translated))</b>	MCTTBIO Co, a South Korean cell therapy product manufacturer, has filed an initial public offering application for regulatory approval, according to a stock exchange statement. MCTTBIO aims to raise up to KRW 18bn (USD 15.2m) through the IPO, according to a statement on the Korean Exchange on 14 September.
14- Sep	<b>Shanghai Fosun Pharmaceutical actively seeking acquisition opportunities (translated)(Source: Hong Kong Economic Journal)</b>	Shanghai Fosun Pharmaceutical [HKG: 2196], a Chinese pharmaceutical company, is actively seeking acquisition opportunities, the Hong Kong Economic Journal reported. The company is seeking opportunities to acquire privately-held hospitals in China, and it is hoped that the number of hospital beds under the company's management.
13- Sep	<b>Baicao Traditional Chinese Medicine 51.01% stake will be acquired by Zhejiang Jolly Pharmaceutical for CNY 130m (Source: Stock Exchange Announcement (Translated))</b>	Listed Chinese entity Zhejiang Jolly Pharmaceutical [Zuo Li Yao Ye; SZ: 300181] has signed an agreement with private investors Chen Zhaorong and Chen Huan over acquiring a 51.01% stake in Baicao Traditional Chinese Medicine for CNY 130m (USD 20.39m).
11- Sep	<b>Dong-A Socio Holdings to sell 49% in DMB to Meiji Seika Pharma for USD 34m (Source: Stock Exchange Announcement (Translated))</b>	Dong-A Socio Holdings (KRX:000640), a listed South Korean pharmaceutical company, has agreed to sell a 49% stake in DMB to Meiji Seika Pharma for about USD 34m, according to a stock exchange announcement and Edaily. DMB is a South Korean biosimilar developer and a wholly owned subsidiary of Dong-A Socio; Meiji Seika is an unlisted Japanese pharmaceutical company.
11- Sep	<b>Elder Pharmaceuticals may sell its factories in Uttarakhand and Maharashtra – report (Source: Mint)</b>	Elder Pharmaceuticals [BOM:532322], the Indian pharma, may decide to sell its factories located in both Maharashtra and Uttarakhand, in addition to some real estate assets, to help raise capital to repay its creditors, mint reported.
11- Sep	<b>Elder Pharmaceuticals denies report about planned asset sale to repay debt (Source: Stock Exchange Announcement(s) (Edited))</b>	With reference to a report in the mint on 11 September 2015 titled "Elder Pharma to sell assets to clear debt", the India-based Elder Pharmaceuticals (BOM: 532322) gave the following clarification to the BSE later in the day. "We wish to inform you that the Company has always promptly informed/intimated to the BSE/National Stock Exchange of India all the events, information etc.,
11- Sep	<b>Sigma Pharmaceuticals targeting</b>	Sigma Pharmaceuticals [ASX: SIP] is targeting acquisitions to lessen its reliance on

	<b>acquisitions to reduce reliance on government-regulated business (Source: Australian Financial Review)</b>	government-regulated business, the Australian Financial Review reported. The report cited Sigma's chief executive, Mark Hooper, as saying that he is eager to reduce risk by building revenue from areas that do not rely on the Pharmaceutical Benefits Scheme (PBS).
11- Sep	<b>IHH Healthcare unit planning to pursue acquisitions to expand into India (Source: Newswire Round-up)</b>	A unit of IHH Healthcare [KLSE: 5225], the listed Malaysia-based healthcare provider, is planning to pursue acquisitions to expand into India, according to a newswire. The Reuters report cited Parkway Pantai's head of Middle East and South Asia operations, Ramesh Krishnan, who ruled out the possibility of greenfield developments.
11- Sep	<b>Healthscope stake said to interest strategic Asian players – report (Source: Australian Financial Review)</b>	Strategic Asian buyers are believed to have lodged applications with Australia's Foreign Investment Review Board (FIRB) to buy TPG and Carlyle Group's remaining stake in Healthscope [ASX: HSO], the Australian Financial Review reported.
10- Sep	<b>Mindray receives revised take-private proposal, lowered to USD 27 per ADS (Source: Company Press Release(s))</b>	Mindray Medical International Limited [NYSE: MR], a developer, manufacturer and marketer of medical devices, has received a revised non-binding take-private proposal from board executive chairman and co-CEO Li Xiting, Chairman Xu Hang, and co-CEO Cheng Minghe for USD 27 per ADS in cash.
10- Sep	<b>iKang special committee to retain advisors to assist in evaluating take-private proposal (Source: Company press release.)</b>	iKang Healthcare Group, Inc. ("iKang" or the "Company") (Nasdaq:KANG), China's largest private preventive healthcare services provider, today announced that in response to the preliminary non-binding proposal dated August 31, 2015 (the "Proposal") received by the Company's board of directors.
10- Sep	<b>Asian buyers eyeing TPG, Carlyle's remaining stake in Healthscope - report (Source: Australian Financial Review)</b>	Several Asian strategic buyers are interested in purchasing the remaining portion of Healthscope's [ASX: HSO] shares held by TPG and The Carlyle Group, after the two companies have sold a combined 350m Healthscope shares from escrow in a block trade, the Australian Financial Review reported in its Street Talk column.
10- Sep	<b>Watami in talks to sell nursing care unit (Source: Stock Exchange Announcement (Translated))</b>	Watami [TYO:7522], a Japan-based restaurant chain and nursing care business operator, is conducting talks to divest its nursing care unit, the company said in a statement filed to the Tokyo Stock Exchange. Although Watami did not name the companies it is in talks with, the Japanese insurance company Sompo Japan Nipponkoa Holdings [TYO: 8630] said it is considering acquiring the nursing care unit in a separate statement filed to the Tokyo Stock Exchange.
10- Sep	<b>Boditech Med considering pursuing M&amp;A opportunities to expand presence in the Chinese market (translated) (Source: Financial News Daily (Korea))</b>	Boditech Med, a South Korean vitro diagnostics company, is considering pursuing M&A opportunities to expand its presence in the China market, reported Financial News Daily. The company aims to generate an annual sales of KRW 100bn (USD 86m) by 2018, the Korean-language report cited Eui-yeol Choi, the CEO of the company, as speaking in a media conference yesterday.
10- Sep	<b>Watami in talks with Sompo Japan Nipponkoa Holdings, Panasonic concerning sale of Watami no Kaigo - report (translated)(Source: Nihon Keizai Shimbun)</b>	Watami [TYO: 7522], the Japan-based restaurant chain and nursing care business operator, is conducting talks with insurer Sompo Japan Nipponkoa Holdings [TYO: 8630] and Panasonic [TYO: 6752] regarding the sale of its nursing care unit, Watami no Kaigo, the Nihon Keizai Shimbun reported.

<b>10- Sep</b>	<b>Bases Conversion and Development Authority and M Health sign agreement to form joint venture</b> <i>(Source: Business World)</i>	<i>Bases Conversion and Development Authority (BCDA), the Philippines-based, state-owned company, and UK-based M Health Ltd. have signed an agreement to form a joint venture, reported Business World. M Health will be conducting a pre-investment feasibility study for the development of a 160-hectare health care facility located in Clark Green City.</i>
<b>10- Sep</b>	<b>Sun Pharma looks to sell manufacturing facility in Ireland</b> <i>(Source: Newswire Round-up)</i>	<i>Sun Pharmaceutical Industries [BOM: 524715], the Indian pharma, said it is looking to sell its manufacturing facility in Ireland, according to a newswire report. Reuters cited a spokesperson at Sun Pharma on Wednesday (9 September) reporting on the development. The company's manufacturing facility in Ireland has been identified for possible sale, the item noted.</i>
<b>9- Sep</b>	<b>NZ Pharma up for sale, PwC advising – report</b> <i>(Source : The Australian)</i>	<i>NZ Pharma, the New Zealand healthcare business, is up for sale, The Australian reported. According to the report, which did not cite its source, PwC is advising on the sale, which could value the group at up to NZD 200m (USD 125m).</i>
<b>9- Sep</b>	<b>Healthway Medical hires SAC Capital as adviser with regard to company purchase by International Healthway</b> <i>(Source: Stock Exchange Announcement*)</i>	<i>Healthway Medical (SGX: 5NG) has appointed SAC Capital as the independent financial adviser for the proposed acquisition by International Healthway (SGX: 5WA) through a scheme of arrangement, according to a 3 September stock exchange announcement.</i>
<b>9- Sep</b>	<b>Metropolis Healthcare shareholder Velu sells stake to Carlyle</b> <i>(Source: Company press release.)</i>	<i>Global alternative asset manager The Carlyle Group (NASDAQ: CG) today announced that an affiliate of Carlyle Asia Partners IV has bought a stake in Metropolis Healthcare Limited, a multinational chain of pathology laboratories. Carlyle is acquiring the stake held by Dr. GSK Velu and his affiliates.</i>
<b>9- Sep</b>	<b>Jayhawk Capital urges China Cord Blood board to reject Golden Meditech offers</b> <i>(Source: Company Press Release(s) (Edited))</i>	<i>The following is an open letter sent September 9, 2015 to the Board of Directors of China Cord Blood [NYSE:CO] from Jayhawk Capital. We reiterate our conviction that the special committee of the independent directors of China Cord Blood Corp ("China Cord") should REJECT the extremely low privatization offer of USD 6.40 per share from Golden Meditech Holdings Co Ltd ("Golden Med") [HKG:0801].</i>
<b>9- Sep</b>	<b>PharmsWellBio 20.45% stake acquired by Wings Group for KRW 17.8bn</b> <i>(Source: Stock Exchange Announcement (Translated))</i>	<i>PharmsWellBio (KOSDAQ: 043090), a listed South Korean medical equipment maker, announced today that its largest shareholder group has signed a stock agreement to sell a 20.45% stake in the company to Wings Group for KRW 17.8bn (USD 14.9m).</i>
<b>9- Sep</b>	<b>UMP Healthcare files for Hong Kong IPO; JPMorgan is sole sponsor</b> <i>(Source: Stock Exchange Announcement*)</i>	<i>UMP Healthcare Holdings Limited, a Hong Kong-based corporate healthcare solutions provider, has filed an application to list on the Main Board of the Hong Kong stock exchange. JPMorgan is the sole sponsor of the share offer.</i>
<b>9- Sep</b>	<b>Concord Medical announces plans to form JV Beijing Allcure Medical Information Technology with strategic investors</b> <i>(Source: Company Press Release(s) (Edited))</i>	<i>Concord Medical Services [NYSE: CCM], a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced its plan to establish Beijing Allcure Medical Information Technology, according to a press release.</i>

9- Sep	<b>Rayence confirms IPO plan, to file application to clear regulatory approval in November (translated) (Source: ETNEWS)</b>	Rayence, the South Korean X-ray detector maker, plans to go public, ETNews reported, citing CEO Jung-hoon Hyun. Hyun told the Korean language paper that the company will file an application to clear regulatory approval in November, aiming to launch its share trading debut in 1Q16.
8- Sep	<b>Jiangzhong Pharmaceutical to auction its 51% stake in Jiangxi Jointown Pharmaceutical (Source: Stock Exchange Announcement (Translated))</b>	Jiangzhong Pharmaceutical [Jiang Zhong Yao Ye, 600750.SH], a Jiangxi, China-based listed pharmaceutical company, said its board meeting has approved to auction its 51% stake in Jiangxi Jointown Pharmaceutical [Jiang Xi Jiu Zhou Tong]. Jiangxi Jointown Pharmaceutical is a pharmaceutical distributor formed by Jiangzhong Pharmaceutical and Jointown Pharmaceutical Group [Jiu Zhou Tong].
8- Sep	<b>Pangen Biotech plans KOSDAQ IPO, appoints Korea I&amp;S (Source: Stock Exchange Announcement (Translated))</b>	Pangen Biotech, a South Korean company, on 7 September filed an application for regulatory approval to launch an IPO. The company plans to float on the KOSDAQ exchange for medium-sized companies, according to a statement on the Korean Exchange on 8 September. It aims to raise up to KRW 35.4bn (USD 29.7m) through the IPO.
8- Sep	<b>Kimia Farma/Indofarma merger plans cancelled for the time being (translated) (Source: Bisnis Indonesia)</b>	A plan to merge Kimia Farma and Indofarma, two publicly traded state-owned Indonesian pharmaceutical companies, has been cancelled for the time being, Bisnis Indonesia reported. The plan to form a holding company for state-owned pharmaceutical companies by merging Kimia Farma and Indofarma is postponed indefinitely, the Indonesian-language report, which cited Muhammad Zamkhani, a senior official at the Indonesian ministry of state enterprises, noted.
8- Sep	<b>Harmonicare Medical currently in talks for acquisition opportunities in Shanghai (translated) (Source: Hong Kong Economic Times)</b>	Harmonicare Medical (HKG: 1509), a China-based private obstetrics and gynecology specialty hospital group, is currently in talks for potential acquisition opportunities in Shanghai, the online Hong Kong Economic Times reported.
8- Sep	<b>Chongqing Zien Hospital Management 30% stake to be acquired by Huapont Life Science for CNY 37.63m (Source: Stock Exchange Announcement (Translated))</b>	China-based listed Huapont Life Science, [SHE: 002004], formerly called Huapont-Nutrichem [Hua Bang Ying Tai], signed a stake transaction agreement with Chongqing Huibang Tourism [Hui Bang Lv Ye] over buying the latter's 30% stake in Chongqing Zien Hospital Management on 6 September.
8- Sep	<b>Estia Health approached Archer Capital about acquiring Allity - report (Source: The Australian)</b>	Estia Health [ASX: EHE], the Australian aged care provider, has approached Archer Capital about acquiring Allity, the group's main rival, reported the Australian's Dataroom column. The unsourced report noted that the offer was made in August; however, Archer Capital is said to have rebuffed the bid.
7- Sep	<b>CARE Hospitals: Abraaj, PD Hinduja Hospital-Everstone Capital consortium among frontrunners to buy Advent International's stake – report (Source: The Economic Times)</b>	Abraaj, the private-equity player, and Everstone Capital and the India-based PD Hinduja Hospital in consortium are among frontrunners to buy Advent International's stake in the India-based CARE Hospitals. This was reported by The Economic Times, citing undisclosed sources.



7- Sep	<b>Vacopharm shareholder SCIC to exit (Source: Vietnam Economic Times)</b>	Vietnam's State Capital Investment Corp (SCIC) is looking to dispose of its entire 2.19 million shares in domestic pharmaceutical firm Vacopharm, Vietnam Economic Times reported. The report, citing a SCIC announcement, said that the shares represent a 48.57% stake in the company.
7- Sep	<b>Huadong Medicine terminates proposed acquisition of Kremers Urban Pharmaceuticals (Source: Stock Exchange Announcement (Translated))</b>	Huadong Medicine [Hua Dong Yi Yao; SZ: 000963], a Zhejiang-based pharmaceutical company, said in a stock exchange announcement that its board has approved to terminate its proposed acquisition of Kremers Urban Pharmaceuticals. Kremers Urban Pharmaceuticals is a Princeton, New Jersey-based specialty generic drug maker and a subsidiary of Belgian pharmaceutical company UCB SA.
7- Sep	<b>Sienna Cancer Diagnostics appoints PAC Partners to assist ASX listing – report (Source: Australian Financial Review)</b>	Sienna Cancer Diagnostics, an Australia-based privately held biotech company, has appointed PAC Partners to assist with its planned AUD 10m (USD 7.7m) ASX listing, according to an unsourced report in the Australian Financial Review's Street Talk column.
6- Sep	<b>Chuangmei Pharmaceutical files for Hong Kong IPO; Guotai Junan is sole sponsor (Source: Stock Exchange Announcement(s))</b>	Chuangmei Pharmaceutical Co., Ltd., a Southern China-based pharmaceutical distributor, has filed an application to list on the Main Board of the Hong Kong stock exchange. Guotai Jinan international is the sole sponsor of the share offer.
4- Sep	<b>Cipla inks definitive agreements to acquire InvaGen Pharmaceuticals, Exelan Pharmaceuticals (Source: Company Press Release(s) (Edited))</b>	Cipla (BOM:500087), the India-based drug company, on 3 September announced that its UK arm, Cipla EU, has entered into definitive agreements to acquire two US-based companies, InvaGen Pharmaceuticals, New York, and Exelan Pharmaceuticals, Georgia. The transaction being subject to certain closing conditions, is valued at USD 550m and will be an all-cash one.
4- Sep	<b>Cipla in advanced discussions to acquire US business of Hetero Drugs – report (Source: CNBC-TV18)</b>	Cipla (BOM: 500087), the India-based drug company, is engaged in advanced discussions to acquire the US business of the India-based Hetero Drugs, which is operated under the brand Camber Pharmaceuticals. The deal could be made public within a couple of days, this was reported on 03 September 2015 by CNBC-TV18, which cited undisclosed sources as saying.
4- Sep	<b>Lorenzo International not to proceed with planned purchase of medical facilities from Straitsworld (Source: Stock Exchange Announcement(s))</b>	Lorenzo International [SGX:5IE], a Singapore-listed lifestyle furniture manufacturer and designer, has decided not to extend the exclusive period relating to a term sheet for the acquisition of medical facilities from Straitsworld, according to a stock exchange announcement.
4- Sep	<b>Central Transport Hospital sees T&amp;T Group become strategic investor - report (translated) (Source: Bao Dau tu dien tu (baodautu))</b>	Hanoi-based T&T Group has been selected as a strategic investor of Hanoi-based Central Transport Hospital, the first state hospital to be equitised in Vietnam, Baodautu reported, quoting an unnamed source. The Vietnamese-language item said that T&T satisfied all criteria on the capital and financial requirements for the deal.
4- Sep	<b>Infraredx to be acquired by Nipro (Source: Stock Exchange Announcement (Translated))</b>	Nipro [TYO:8086], the Japan-based medical equipment and glass products maker, announced today that its US-based subsidiary Goodman USA will acquire privately held Massachusetts-based medical equipment maker Infraredx. Nipro currently holds a 25.06% stake in Infraredx.

4- Sep	<b>Bangkok Chain Hospital eyed by Middle Eastern investor - report (translated) (Source: Thunhoon)</b>	A Middle Eastern investor is interested in taking over Bangkok Chain Hospital [BKK: BCH], a Thailand-based hospital operator, Thunhoon reported. Citing an unnamed source, the Thai-language report said that the potential buyer has expressed interest in buying small and medium hospital groups in Thailand with Bangkok Chain Hospital among its targets.
2- Sep	<b>Penlon acquired by BPL Medical Technologies (Source: Company Press Release(s) (Edited))</b>	BPL Medical Technologies (“BPL Medical”), an India-based medical devices company backed by global investment bank Goldman Sachs, on 01 September 2015, completed the acquisition of Penlon, a UK-based manufacturer of anaesthesia systems and vaporisers with worldwide distribution networks.
2- Sep	<b>Haisco Pharmaceutical Group subsidiary to control Sensible Medical Innovations for USD 18m (Source: Stock Exchange Announcement (Translated))</b>	HaisThera Scientific Fund I, L.P., the subsidiary of Haisco Pharmaceutical Group [Hai Si Ke; SZ:002653], a China based pharmaceutical company, has signed an agreement to subscribe \$18m to the Series D preferred shares of Sensible Medical Innovations, an Israeli medical device maker.
2- Sep	<b>Lvjing Holding to raise up to USD 1.58bn via new share issue, Tianan Life to become largest shareholder (Source: Stock Exchange Announcement (Translated))</b>	Lvjing Holding [Lv Jing Kong Gu; SHE:000502], a Guangdong-based real estate developer, said in a September 2 stock exchange announcement that it plans to raise up to CNY 10.05bn (USD 1.58bn) via a private placement of new shares.
2- Sep	<b>Amicogen to acquire 51.5% stake in Shandong Lukang Record Pharmaceutical for CNY 159.6m (Source: Stock Exchange Announcement (Translated))</b>	Amicogen (KOSDAQ:092040), a listed South Korean bio-catalyst and enzyme maker, announced today that its BoD has approved to acquire a 51.5% stake in Shandong Lukang Record Pharmaceutical, for CNY 159.6m (USD 24.7m). Shandong Lukang Record Pharmaceutical is an unlisted Chinese pharmaceutical joint venture between Shandong Lukang Pharmaceutical (SHA: 600789) and Shanghai Record Pharmaceuticals.
2- Sep	<b>Ascletris secures USD 35m financing (Source: Company press release.)</b>	Ascletris announced today the completion of a USD 35m (RMB 220m) financing. The investment was led by C-Bridge Capital, joined by Tasly Pharmaceutical and Singapore-based Pavilion Capital. The valuation of the Company before financing was USD 300m.
1- Sep	<b>Suzhou Tianma Specialty Chemicals plans to buy pharmaceutical assets from controlling shareholder (Source: Stock Exchange Announcement (Translated))</b>	Suzhou Tianma Specialty Chemicals [Tian Ma Jing Hua; SZ: 002453] plans to acquire Suzhou Tianma Pharma Group Tianji Bio-Pharmaceutical [Tian Ji Sheng Huo] and Jiangsu Feima Pharmaceutical [Fei Ma Yao Ye] from Changzhou Tianma Group.
1- Sep	<b>Godrej Agrovet makes open offer for 26.05% stake in Astec Lifesciences (Source: Stock Exchange Announcement(s) (Edited))</b>	Kotak Mahindra Capital Company (“Manager to the Open Offer”) has submitted to the BSE a copy of a Public Announcement (“PA”) regarding Open Offer for acquisition of 5,067,259 equity shares (“Offer”/“Open Offer”) of the India-based Astec Lifesciences (BOM:533138) (“Target Company”) by Godrej Agrovet (“Acquirer”), pursuant to and in compliance with regulations 3(1) and 4 of the Securities and Exchange Board of India

*(Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and subsequent amendments thereto (the "SEBI (SAST) Regulations").*

<b>1- Sep</b>	<b><i>New Ray Medicine International net USD 8.5m through share placement partly for potential acquisitions and investments (Source: Stock Exchange Announcement* )</i></b>	<i>New Ray Medicine International [HKG: 6108], a pharmaceutical distributor based in China, announced that it has signed an agreement to raise net proceeds of approximately HKD 66.2m (USD 8.5m) through a share placement partly for potential acquisitions and investments.</i>
<b>1- Sep</b>	<b><i>SSY Group to acquire Jiangsu Bosheng Yi Yong Xin Cai Liao for CNY 199.5m (Source: Stock Exchange Announcement* )</i></b>	<i>SSY Group (HKG: 2005), a pharmaceutical products manufacturer, announced that it has signed an agreement to acquire Jiangsu Bosheng Yi Yong Xin Cai Liao Co., Ltd. for CNY 199.5m (USD 31.3m). Jiangsu Bosheng Yi Yong Xin Cai Liao is principally engaged in the manufacturing and sales of medicinal butyl rubber stoppers, synthetic polyisoprene liners and non-PVC multi-layer co-extrusion film for infusion solution.</i>
<b>1- Sep</b>	<b><i>Winsan (Shanghai) Medical Science and Technology share trading halt remains on 1 September, planning to buy SHL Telemedicine (Source: Stock Exchange Announcement (Translated))</i></b>	<i>Winsan (Shanghai) Medical Science and Technology [Yun Sheng Shi Ye; SHA: 600767], a China-based listed medical equipment maker, said the share trading in the company, which started on 25 August, will remain on 1 September. According to the stock exchange announcement by the listed company today, its largest shareholder Shanghai Jiuchuan Investment signed the M&amp;A agreement and plan with Jinoran Mergers (2015) Ltd over buying SHL Telemedicine Ltd.</i>

---

## DISCLAIMER

---

This Information Package is distributed by Quadria Capital Investment Management ('Quadria Capital') upon the express understanding that no information herein contained is proprietary or has been independently verified. Further, no representation or warranty expressed or implied is made nor is any responsibility of any kind accepted with respect to the completeness or accuracy of any information. Also, no representation or warranty is expressed or implied is made that such information in any respect as of any date or dates after those stated herein with respect to any matter concerning any statement made in this Information Package. Quadria Capital and its Managing Partners, employees, agents and consultants shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from, or for any omissions from the Information Package. All recipients of the Information Package should make their own independent evaluations and should conduct their own investigation and analysis and should check the accuracy, reliability and completeness of the Information and obtain independent and specific advice from appropriate professional advisers, as they deem necessary.

Where this Information Package summarizes the provisions of any other document, that summary should not be relied upon and the relevant documentation must be referred to for its full effect.



QUADRIA  
CAPITAL

**Abrar Mir**  
Managing Partner

**Quadria Capital Investment Management Pte. Ltd.**  
11A Stanley Street, Singapore 068730  
D +65 6805 9681 M +65 8522 1033  
abrar.mir@quadriacapital.com | www.quadriacapital.com



QUADRIA  
CAPITAL

**Dr. Amit Varma**  
Managing Partner

**Quadria Capital Investment Advisors Pvt. Ltd.**  
D-1, Clarion Collection, Shaheed Jeet Singh Marg, New Delhi – 110 016  
D +91 11 4953 9901 M +91 98 1838 5665  
amit.varma@quadriacapital.com | www.quadriacapital.com

*This publication does not constitute an offer of, or the solicitation of, an offer to buy or subscribe for, any financial instrument or investment, nor shall it (or any part of it or the fact of its distribution) form the basis of, or be relied on in connection with or act as any inducement to enter into, any contract or commitment whatsoever.*